Document Detail

Protecting against ischemia-reperfusion injury: antiplatelet drugs, statins, and their potential interactions.
MedLine Citation:
PMID:  20955429     Owner:  NLM     Status:  MEDLINE    
Statins and antiplatelet agents are currently used as therapeutic agents for patients with acute myocardial infarction. Statins limit myocardial infarct size by activating phosphatidylinositol-3-kinase (PI3K), ecto-5'-nucleotidase, Akt/endothelial nitric oxide synthase (eNOS), and the downstream effectors inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Inhibition of PI3K, adenosine receptors, eNOS, iNOS, or COX-2 abrogates the protective effects of statins. At >5 mg/kg, aspirin attenuates the myocardial infarct-size-limiting effect of statins. In contrast, the combination of low-dose atoravastatin with either the phosphodiesterase-III inhibitor cilostazol or the adenosine reuptake inhibitor dipyridamole synergistically limits infarct size. Low-dose aspirin with dipyridamole started during ischemia augmented the infarct-size-limiting effects of simvastatin. In contrast, high-dose aspirin blocked the protective effect of simvastatin. The combination of dipyridamole with low-dose aspirin and simvastatin resulted in the smallest infarct size. According to the most current data available, we believe that antiplatelet regimens may require modification for patients who are receiving statins.
Yumei Ye; Jose R Perez-Polo; Yochai Birnbaum
Related Documents :
15580389 - Heparin-induced thrombocytopenia after coronary artery bypass grafting with cardiopulmo...
18243369 - Intermittent heparin infusion in children with ischemic heart disease caused by kawasak...
7545449 - Effects of aprotinin on blood loss, heparin monitoring tests, and heparin doses in pati...
17161049 - Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk pat...
14976449 - Gabexate mesilate and heparin responsiveness in coronary patients.
946309 - Selective coronary arteriography. risk in a community hospital.
22178059 - Masp-2 activation is involved in ischemia-related necrotic myocardial injury in humans.
20571889 - Sepsis-induced cardiomyopathy: a review of pathophysiologic mechanisms.
20585009 - Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Annals of the New York Academy of Sciences     Volume:  1207     ISSN:  1749-6632     ISO Abbreviation:  Ann. N. Y. Acad. Sci.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-10-19     Completed Date:  2010-11-09     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  7506858     Medline TA:  Ann N Y Acad Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  76-82     Citation Subset:  IM    
Copyright Information:
© 2010 New York Academy of Sciences.
Department of Biochemistry and Molecular Biology, The University of Texas Medical Branch, Galveston, Texas, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aspirin / administration & dosage
Dipyridamole / administration & dosage
Drug Interactions
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
Models, Cardiovascular
Myocardial Infarction / drug therapy,  pathology,  physiopathology
Myocardial Reperfusion Injury / pathology,  physiopathology,  prevention & control*
Platelet Aggregation Inhibitors / administration & dosage*
Simvastatin / administration & dosage
Tetrazoles / administration & dosage
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Platelet Aggregation Inhibitors; 0/Tetrazoles; 50-78-2/Aspirin; 58-32-2/Dipyridamole; 79902-63-9/Simvastatin; N7Z035406B/cilostazol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of dipyridamole during acute stroke: exploring antithrombosis and neuroprotective benefits.
Next Document:  Reperfusion of chronic tissue ischemia: nitrite and dipyridamole regulation of innate immune respons...